LENZ

In the past six months, LENZ Therapeutics' stock price lost approximately 50% since May 31, 2026, primarily due to widening net losses and high operating expenses associated with the commercial launch of VIZZ. The company reported a net loss of $31.9 million for fiscal Q2 2026, driven by $39.4 million in selling, general, and administrative (SG&A) expenses for the VIZZ launch, and its cash position declined from $258.4 million to $220.0 million. Despite these challenges, LENZ reported a narrower-than-expected loss and a significant revenue beat in Q2 2026, with total revenue reaching $5.5 million, attributed to early traction for VIZZ and license income from overseas partnerships. Following the Q2 2026 earnings release, the stock initially fell by 2.8% but then rose by 7.49% after hours. Other events impacting the stock include the company's partnership with Sarah Jessica Parker for a direct-to-consumer campaign, anticipated to launch in Q1 2026, and the expansion of its sales organization from 88 to 117 territories in Q2 2026 to support growing demand.